M E D I A R E L E A S E
December 24, 2025
Ministry of Health Advises on Recall of Blood Pressure Drug
Port of Spain, December 24, 2025: The Ministry of Health (MoH), via its Chemistry, Food and Drug Division (CFDD), advises the public of a voluntary recall affecting specific lots of Bisoprolol Fumarate and Hydrochlorothiazide Tablets, a generic medication used to treat hypertension.
The recall was initiated by Glenmark Pharmaceuticals Inc. in coordination with the U.S. Food and Drug Administration (FDA) after routine quality testing identified a potential cross-contamination issue. Trace amounts of another drug, ezetimibe, a medication used to treat high cholesterol, were detected in reserve samples of the product, which should not have been present in the blood pressure medication.
The following lots of Bisoprolol Fumarate and Hydrochlorothiazide Tablets (2.5 mg/6.25 mg) are included in the recall:
| Dosage Strength | Bottle Size (Count) | NDC (National Drug Code) | Lot Number (LOT) | Expiration Date (EXP) |
| Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5mg/6.25mg | 30-count | 68462-878-30 | 17232401 | November 2025 |
| Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5mg/6.25mg | 100-count | 68462-878-01 | 17232401 | November 2025 |
| Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5mg/6.25mg | 500-count | 68462-878-05 | 17232401 | November 2025 |
| Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5mg/6.25mg | 30-count | 68462-878-30 | 17240974 | May 2026 |
| Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5mg/6.25mg | 100-count | 68462-878-01 | 17240974 | May 2026 |
| Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5mg/6.25mg | 500-count | 68462-878-05 | 17240974 | May 2026 |
A total of 11,136 bottles of these products have been affected by the recall.
While FDA’s classification of this recall is Class III, indicating that exposure to the trace contaminant is not likely to cause adverse health effects, the Ministry is urging appropriate precaution.
Therefore, out of an abundance of caution, the Ministry advises persons who may have purchased or are currently in possession of the affected products to discontinue use immediately and return the medication to the place of purchase. Anyone with health concerns should consult with their healthcare provider as patients should not abruptly stop antihypertensive medication without professional guidance.
Additional information can be obtained by contacting the Office of the Director of the Chemistry, Food and Drugs Division via email at cfdd@health.gov.tt or phone at 217-4664 ext. 13101.
###
